Skip to Search
Skip to Navigation
Skip to Main Content
Skip to Footer
About Us
Life Sciences Publications
Our Medicines
Topic Articles
Topic Discussions
Login
Google Translate
Select language
English
French
Spanish
Login
Username
*
Password
*
Staff Login
×
Google Translate
Select language
English
French
Spanish
Login
Menu
Site Search
Search Options
Resources
Everything
Advanced Search
Uptodate
All
Title Search
Author
Patients & Caregivers
Healthcare Providers
Researchers & Partners
Investors
menu
About Us
Life Sciences Publications
Our Medicines
Topic Articles
Topic Discussions
Google News
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Q3 2024 EPS Estimates for Sage Therapeutics, Inc. (NASDAQ:SAGE) Lifted by Analyst - Defense World
The Goldman Sachs Group Lowers Sage Therapeutics (NASDAQ:SAGE) Price Target to $11.00 - MarketBeat
Sage Therapeutics, Inc. to Post Q1 2025 Earnings of ($1.75) Per Share, Wedbush Forecasts (NASDAQ:SAGE) - MarketBeat
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - Business Wire
Sage Therapeutics (NASDAQ:SAGE) Shares Gap Down to $13.08 - Defense World
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical - Yahoo Finance
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical - Yahoo Finance
Sage Therapeutics (NASDAQ:SAGE) Given New $13.00 Price Target at Robert W. Baird - Defense World
Sage Therapeutics (NASDAQ:SAGE) Given Neutral Rating at HC Wainwright - Defense World
Sage Therapeutics downgraded to Neutral from Overweight at JPMorgan - TipRanks
Pages
1
2
3
4
5
6
7
8
9
next ›
last »
×